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CYTOMEGALOVIRUS (CMV) INFECTION IN ALLOGENEIC NON-MYELOA-
BLATIVE STEM CELL TRANSPLANTATION RECIPIENTS
Chandrasekar, P.1, King, R.2, Dansey, R.2, Akhtar, A.2, Mellon-Rep-
pen, S.2, Alangaden, G.1 1. Infectious Disease Division, Detroit, MI; 2.
Bone Marrow Transplant, Detroit, MI.
Background: Non-myeloablative technique of allogeneic stem
cell transplantation is recent and increasingly popular; data regard-
ing CMV infection are limited in such transplant recipients. Meth-
ods: We examined our data on patients undergoing non-myeloa-
blative transplantation (NMT) during Sept 2000-Dec 2002.
Results: Thirty-one patients (men 16, mean age 54; women 15,
mean age 47) underwent non-myeloablative transplantation
(NMT) during Sept 2000-Dec 2002 (Number of patients: 3-2000;
16-2001; 12-2002). Major underlying diseases were renal cell car-
cinoma (11), myeloma (5), Non-Hodgkin’s lymphoma (5) and
breast cancer (3). Of 31 patients, 10 received matched unrelated
donor stem cells. Preparative regimens were Fludarabine with
cyclophosphamide (19 patients) or ﬂudarabine with total body
irradiation (12 patients). Most (29/31) received peripheral blood
stem cells. Mean duration of neutropenia was 6.6 days (range 0-16).
Fifteen of 31 patients were CMV seropositive. None received
prophylaxis against CMV; CMV antigen (pp65) test was routinely
done once weekly. CMV antigenemia occurred in 12 patients (with
viremia in 3), 9 of whom were seropositive and 3 seronegative, after
a mean duration of 56 days (range 24-165) from transplant. Anti-
genemia after 100 days occurred in only 1 patient. Four of 12
patients with antigenemia had received stem cells form unrelated
donors. None developed CMV disease. Of the total 31 patients
transplanted, 19 died. CMV antigenemia was of low level in most
patients with prompt response to IV ganciclovir. Conclusions:
Our preliminary data demonstrate that CMV infection is common
in NMT recipients; routine surveillance and pre-emptive therapy
with ganciclovir are effective in preventing CMV disease.
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ANTI-DONOR ISOAGGLUTININ REDUCTION AND PURE RED CELL APLA-
SIA AFTER MAJOR ABO-INCOMPATIBLE HSCT
Stussi, G.1, Bucheli, E.1, Passweg, J.R.2, Halter, J.1, Schanz, U.1,
Gmuer, J.1, Gratwoh, L.A.2, Seebach, J.D.1 1. University Hospital,
Zurich, Switzerland; 2. University Hospital, Basel, Switzerland.
Posttransplant pure red cell aplasia (PRCA) occurs after major or
bidirectional ABO-incompatible HSCT and presumably is caused
by the persistence or a secondary rise of anti-donor host B cells.
However, it is not known, whether the incidence of PRCA depends
on the level and/or reduction of anti-donor isoagglutinins prior to
HSCT. We performed a retrospective two-center analysis of 153
consecutive patients receiving major (n  123) or bidirectional
(n  46) ABO incompatible, allogeneic HSCT between 1980 and
2002. Posttransplant PRCA was deﬁned as reticulocyte count of
less than 1% for more than 100 days along and a lack of RBC
precursors in a bone marrow specimen. In one center, isoaggluti-
nins of the recipient were removed by plasma exchange and/or
in-vivo absorption (IVA) with pretransplant transfusion of donor-
type RBC. Consequently, these patients received exclusively do-
nor-type RBC after HSCT. The other center depleted donor stem
cells from RBC and transfused recipient- or O-type RBC as long as
anti-donor isoagglutinins were present. Overall, 12 patients devel-
oped PRCA after HSCT (12/153, 7.8%). All received HSCT from
a major ABO-incompatible donor. The mean RBC take was de-
layed to 224 d in patients with PRCA (range 143-382 d) compared
to 24 d and the requirement for RBC transfusions was increased
(36 vs. 12, p  0.001). RBC engraftment was associated with a
simultaneous decrease of anti-donor isoagglutinins (11/12). Re-
markably, 9/12 patients with PRCA were transplanted in the center
where isoagglutinin titers were not reduced prior to HSCT. In this
center, 9/46 patients (20%) developed PRCA, whereas only 3 cases
occurred in the other center (3/107, 3%, p  0.001). Patients with
PRCA had higher pretransplant isoagglutinin titers (median 1:64
vs. 1:16, p  0.001). Pretransplant IVA resulted in hemolysis, but
had no serious side effects. The time to RBC engraftment was also
delayed after exclusion of patients with PRCA indicating a general
negative effect of anti-donor isoagglutinins on erythropoiesis (p 
0.005). Beside pretransplant IVA, peripheral stem cell source was
the only signiﬁcant variable in multivariate analysis positively as-
sociated with RBC engraftment. In summary, PRCA after HSCT
depends on the levels and/or reduction of pretransplant anti-donor
isoagglutinins. IVA of these antibodies by transfusions of incom-
patible RBC seems to be a feasible, safe, and cost-effective method
to prevent the occurrence of PRCA.
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PARTIAL T CELL DEPLETION FOR UNRELATED DONOR BMT FOR CHIL-
DREN WITH SEVERE APLASTIC ANEMIA (SAA): ENGRAFTMENT WITH
MINIMAL GVHD
Bunin, N., Leahey, A., Grupp, S., Pierson, G., Monos, D. Children’s
Hospital of Philadelphia, Philadelphia, PA.
Unrelated donor BMT for SAA is reserved for patients who lack
an HLA identical sibling, and fail medical therapy. However,
increased graft rejection is a potential problem in these heavily
transfused patients (pts), and the risk of severe GVHD is also
increased with unrelated donors. Improved techniques in HLA
typing to ensure molecular matching may decrease the risk of
GVHD, but may limit donor availability. Partial T cell depletion
may decrease the risk of severe GVHD, while still maintaining
sufﬁcient donor T lymphocytes to ensure engraftment. We report
on 12 patients with SAA who underwent unrelated donor BMT.
Pts had failed medical therapy with ATG, steroids and cyclospor-
ine (CSA) (9) or relapsed following initial responses (3). Median
age was 6 yrs (1-20), and there were 5 males, 7 females. Median
time from diagnosis of SAA to BMT was 466 days(155-1084).
Donors were serology class I (A, B) and DRB1 matched for 4 pts,
mismatched at the A locus for 3 pts, at B locus for 3 pts, and at DR
for 2 pts. Conditioning included Ara-C 12 g/m2, cyclophospha-
mide (CPM) 90 mg/kg and total body irradiation 12-13.2 Gy for 4
pts, and thiotepa 10 mg/kg, CPM 120 mg/kg and TBI 12 Gy for 8
pts. The last 7 pts received ALG 1.5 mg/kg for 3 days prior to
marrow infusion. In vitro partial T cell depletion was T10B9 and
complement (8 pts) or OKT3 and complement (4 pts). Cyclospor-
ine was used for 3 months post BMT and then tapered. Median
nucleated cell dose post T depletion was 0.8 x 108/kg (0.24-3.2),
and median CD3 cell dose was 1 x 106/kg (0.2-9.2). All patients
engrafted, with a median time of 18 days to ANC  500 (14-34),
and all but one pt became platelet transfusion independent. Acute
GVHD grades I-II developed in 4 pts; two developed limited
cGVHD. Nine pts (75%) are alive 3-147 mos post BMT and
transfusion independent. Morbidity included intractable VOD in a
pt with Schwachman-Diamond syndrome, who underwent suc-
cessful related donor live transplant. Three pts died at d 165, 237
and 282 from resistant CMV, renal failure, and PCP respectively.
This series suggests that an aggressive immunosuppressive condi-
tioning regimen with partial T cell depletion results in successful
engraftment and minimal GVHD in pediatric patients with SAA,
even with HLA mismatched donors.
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ANTI-THYMOCYTE-GLOBULIN (ATG) IN THE NONMYELOABLATIVE
CONDITIONING FOR CANINE HEMATOPOIETIC CELL TRANSPLANT
(HCT)
Diaconescu, R.1, Little, M.-T.1, Leisenring, W.1,2, Yunusov, M.1,
Hogan, W.1, Sorror, M.1, Baron, F.1, Storb, R.1,2 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. University of Washington,
Seattle, WA.
We tested whether pretransplant immunosuppression with ca-
nine-speciﬁc rabbit ATG (SangStat), combined with 1 Gy total
body irradiation (TBI) and posttransplant mycophenolate mofetil/
cyclosporine (MMF/CSP) would assure stable engraftment in our
canine HCT model. First, pharmacokinetic studies were done in 4
dogs, with cumulative ATG doses of 2–5 mg/kg, subcutaneously.
ATG was most effective in depleting peripheral T cells (CD4
and CD8), intermediate on B cells and did not deplete other
blood cells. Lymph node biopsies taken after 2 mg/kg ATG
showed 50% T-cell depletion. Serum levels of ATG peaked at
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